Health Care·Biotechnology·$3.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | -$0.72 | N/A | +2.70% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | -$0.72 | N/A | +2.70% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a sense of cautious optimism about the company's direction. They emphasized their commitment to innovation and growth.
Management highlighted ongoing investments in R&D to drive future growth.
They expressed confidence in their long-term strategy despite current challenges.
Twist Bioscience's earnings report showed a smaller-than-expected loss per share, which led to a positive stock reaction, with shares rising by 4.05%. The company did not provide revenue figures or guidance, but management's focus on R&D suggests they are looking to strengthen their market position. Investors may view the EPS beat as a sign of resilience in a challenging environment.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ON SEMICONDUCTOR COR
Feb 1, 2021